Cramer Interviews Acorda Therapeutics CEO

Acorda CEO Projects $255 Million From AMPYRA
Acorda CEO Projects $255 Million From AMPYRA   

On Tuesday, Acorda Therapeutics CEO Ron Cohen appeared on “Mad Money” to offer insight on his company’s multiple sclerosis drug "AMPYRA.”

To Cramer, the drug could be a huge driver for the stock . But he wanted to get the perspective of the company’s CEO, so he was happy to chat with Cohen. Watch the video to see the full interview.



Call Cramer: 1-800-743-CNBC

Questions for Cramer? madmoney@cnbc.com

Questions, comments, suggestions for the Mad Money website? madcap@cnbc.com

Cramer's New Book